Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Inflammation and the immune system

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Microglia are implicated in the progression of Alzheimer's disease (AD) pathology from its earliest stages, suggesting that cerebrospinal fluid (CSF) microglia profiling across clinical AD stages can aid in treatment development and monitoring. We analyzed two CSF cohorts (n = 834) that span from unimpaired controls to preclinical and dementia AD stages, identifying 109 dysregulated microglia-related proteins. Enrichment analyses revealed innate immune processes and cellular recruitment in preclinical AD, whereas AD dementia revealed adaptive immunity and macrophage responses. Next, we aligned the in vivo microglia protein profiles with ex vivo-derived microglial transcriptomic signatures, such as disease-associated microglia phenotypes. Transcriptomic signatures were not specific to either clinical stage but spanned both. We classified an 18-protein panel highlighting distinct changes between the preclinical and dementia stages. Our findings underscore the potential of microglia-based biomarker research for AD staging, offering insights into microglia dynamics in clinical AD stages and how transcriptomic signatures translate to proteomic profiles.

What this study adds

Evidence grade: Low

The record lists 834 participants. Analyzing cerebrospinal fluid from 834 people, this study identified 109 dysregulated microglia-related proteins and an 18-protein panel that differed between preclinical and dementia stages of Alzheimer's disease. This is biomarker research for staging and monitoring, not a treatment or prevention.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Blujdea, E. R., van Bokhoven, P., Adami, P. V. M., Marshe, V. S., Vromen, E., Hok-A-Hin, Y. S., et al. (2026). Microglia protein profiles in CSF across Alzheimer’s disease clinical stages. Nature Aging. https://doi.org/10.1038/s43587-026-01088-0

Vancouver

Blujdea ER, van Bokhoven P, Adami PVM, Marshe VS, Vromen E, Hok-A-Hin YS, et al. Microglia protein profiles in CSF across Alzheimer’s disease clinical stages. Nature Aging. 2026. doi:10.1038/s43587-026-01088-0. PMID: 41814022.

BibTeX

@article{blujdea2026-41814022,
  author  = {Blujdea, Elena Raluca and van Bokhoven, Pieter and Adami, Pamela V. Martino and Marshe, Victoria S. and Vromen, Ellen and Hok-A-Hin, Yanaika Sylvana and Boiten, Walter A. and Irwin, David John and others},
  title   = {{Microglia protein profiles in CSF across Alzheimer’s disease clinical stages}},
  journal = {Nature Aging},
  year    = {2026},
  doi     = {10.1038/s43587-026-01088-0},
  pmid    = {41814022},
  url     = {https://doi.org/10.1038/s43587-026-01088-0}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

Analyzing cerebrospinal fluid from 834 people, this study identified 109 dysregulated microglia-related proteins and an 18-protein panel that differed between preclinical and dementia stages of Alzheimer's disease. This is biomarker research for staging and monitoring, not a treatment or prevention.

Study details

How this study scored 51/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 1 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 1 of 5; Impact for its field and year 4 of 6; Cited by studies here 1 of 6; Still being cited 1 of 4; Senior author's track record 2 of 4; Institution's track record 2 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 51 of 100.51 of 100 points earned49 not earned

Published in a leading specialty journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Nature Aging)
Journal's citation record 1 / 4 Nature Aging: journal h-index 103 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 2 / 4 834 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 5 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 2.5 citations a year over 2 year(s) since 2026
Impact for its field and year 4 / 6 Cited 12.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 1 / 4 Cited 5 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Lisa Vermunt: h-index 26 (OpenAlex, whole career)
Institution's track record 2 / 3 University of Pennsylvania: institution h-index 1,859 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 38 institution(s) in 7 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41814022)
Free to read 2 / 2 Free to read
Total 51 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 29.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Inflammation and the immune system from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Inflammation and the immune system

See all studies in Inflammation and the immune system →